SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Winston Churchill

PatientWinston Churchill
Date of birth1947-11-30
IdentifiersMRN HR-ET001-SYN; SSN (made up) 000-01-8846
Document date2026-08-19
AuthorBeatrice Okafor, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-week stroke and blood pressure review. [S]

History of Present Illness

Mr. Churchill returns eight weeks after his stroke and three weeks after the sick visit at which amlodipine was reduced to 5 mg for orthostatic lightheadedness. The lightheadedness resolved within two days, and his home standing pressures have been 120 to 130 systolic. He has had no falls and no new neurological symptoms. He walks outdoors without a stick and his handwriting is nearly normal. He has started chairing meetings at work again, for half days. The 30-day heart monitor was returned five days ago. He is down to about four cigars a day and no longer drinks in the afternoon. His mood is better and he cries less often. [S]

ElementDetail
Interval changeOrthostatic symptoms resolved after reducing amlodipine
FunctionWalking outdoors without a stick; handwriting nearly normal; half days at work
Home blood pressureStanding 120 to 130 systolic
Tobacco and alcoholAbout four cigars a day; no afternoon drinking
MoodBetter; tearful less often

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving
CardiovascularNegativeNo lightheadedness, chest pain, or palpitations
NeurologicalNegativeNo new weakness, numbness, speech change, or visual loss
MusculoskeletalNegativeNo muscle aches on atorvastatin
PsychiatricNegativeMood improving; sleeping better; no thoughts of self-harm; PHQ-9 score 6

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily for 21 days with clopidogrelOne tablet by mouth dailyOral route2026-06-23 to 2026-07-14completedS
Clopidogrel 75 mg oral tablet, one tablet by mouth daily (after a 300 mg loading dose in the hospital)One tablet by mouth dailyOral route2026-06-23activeS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-06-23activeS
Amlodipine 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-06-26 to 2026-07-01completedS
Amlodipine 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-07-01 to 2026-07-29completedS
Lisinopril 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-07-15activeS
Amlodipine 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-07-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-19Body height168cmS
2026-08-19Body weight79kgS
2026-08-19Body mass index (BMI) [Ratio]28kg/m2S
2026-08-19Systolic blood pressure128mm[Hg]S
2026-08-19Diastolic blood pressure76mm[Hg]S
2026-08-19Heart rate70/minS
2026-08-19Respiratory rate16/minS
2026-08-19Body temperature36.7CelS
2026-08-19Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-19Cholesterol [Mass/volume] in Serum or Plasma128mg/dL<=199 mg/dLNormalS
2026-08-19Cholesterol in HDL [Mass/volume] in Serum or Plasma48mg/dL>=40 mg/dLNormalS
2026-08-19Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2026-08-19Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation58mg/dL<=99 mg/dLNormalS
2026-08-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-56 U/LNormalS
2026-08-19Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-08-19Total score [AUDIT-C]5{score}S

Physical Exam

Vital signs recorded on 2026-08-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell and animated
Orthostatic vital signsSeated 128/76 mmHg; standing 124/74 mmHg, no symptoms
HeartRegular rhythm; no murmur
NeurologicalFaint left pronator drift only; speech normal
GaitNormal pace without a stick; slight left circumduction when tired

Problems

ProblemClinical statusVerificationCodeProvenance
Mild left hemiparesis and dysarthria after a right-hemisphere lacunar infarct eight days before intake; synthetic modern episode linked to the documented 1953 strokeactiveconfirmed I69.354S — Synthetic modern diagnosis; the 1953 stroke remains D in the history.
Essential hypertensionactiveconfirmed I10S — Synthetic diagnosis supported by the documented raised blood pressure after the 1953 stroke.
Nicotine dependence, cigars, six to eight a dayactiveconfirmed F17.290S — Synthetic coded diagnosis echoing the documented lifelong cigar smoking.
Orthostatic hypotension after antihypertensive intensification in hot weather, resolved after reducing amlodipineresolvedconfirmed I95.1S — Synthetic medication-related intercurrent problem at an unscheduled visit; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure seated and standing, weight and BMIEvery visitCompleted todaySeated 128/76 mmHg, standing 124/74 mmHg; weight 79.0 kg; target met without orthostatic hypotension
LaboratoryLipid panel4 to 12 weeks after starting or changing a statin, then every 3 to 12 monthsCompleted todayEight weeks after starting atorvastatin 80 mg. LDL cholesterol 58 mg/dL, below the 70 mg/dL target
LaboratoryALTBaseline, then only with symptomsCompleted today28 U/L, normal
LaboratoryBasic metabolic panel1 to 2 weeks after starting an ACE inhibitor, then every 6 monthsUp to dateDrawn at the sick visit two weeks after lisinopril was started: potassium 4.6, creatinine 1.12 mg/dL; next in about six months
ImagingProlonged cardiac rhythm monitoringAt least 30 days within 6 months of the strokeCompleted today30 days of monitoring reviewed: sinus rhythm throughout, no atrial fibrillation or flutter
Medication safetyAntithrombotic and statin adherenceEvery visitCompleted todayTaking clopidogrel and atorvastatin; no bleeding or myalgia
ExaminationFall-risk assessmentEvery visitCompleted todayOne near-fall with orthostatic hypotension three weeks ago; none since
SurveyDepression screen (PHQ-9)First post-stroke visit, then periodically while symptoms persist; at least yearlyCompleted today6, down from 8; item 9 scored 0; no treatment needed
SurveyAlcohol use (AUDIT-C)Every visitCompleted today5, down from 8; brief intervention repeated
Self-managementTobacco useEvery visitCompleted todayAbout four cigars a day; goal of three agreed
ExaminationObstructive sleep apnea evaluationConsider for all after strokeDeferredSTOP-Bang 3 (age, sex, and hypertension), with no loud snoring, witnessed apneas, or sleepiness beyond his habitual afternoon nap. Sleep testing was offered and he declined it for now, a deviation from the protocol recorded here. No harm is evident; corrective action: the question will be asked again at each review and testing arranged if symptoms appear
ReferralPhysical and occupational therapyThrough recoveryCompleted todayContinuing; expected discharge next month
SurveyCognitive screen (MoCA)Again within the first yearDuePlanned at the annual wellness visit
Medication safetyInfluenza vaccinationYearlyDueThis season's vaccine due in the autumn

Goal progress:

Guideline basis: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021); 2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke (2024); CMID: Clinical Monitoring Intelligence Database, stroke/TIA, hypertension, and depression monographs (2026)

Follow-up: Three-month stroke review in about seven weeks. Next scheduled visit 2026-10-07: three-month stroke review before returning to public speaking. [S]